Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron (Nasdaq: GERN) announced the grant of non-statutory stock options to purchase 2,910,780 shares of common stock as inducements for newly hired employees. The options were granted on May 15, 2024, at an exercise price of $3.90 per share, matching the closing price on the grant date. The options, which have a 10-year term, will vest over four years, starting with 12.5% on the six-month anniversary of employment, followed by equal monthly installments over the next 42 months. These inducements are in line with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported financial results for the first quarter of 2024, including a net loss of $55.4 million and revenues of $304,000. The company has completed commercial team onboarding and is preparing for the potential U.S. launch of imetelstat pending FDA approval. The Phase 3 IMpactMF trial continues with updated timelines. Geron expects total operating expenses for fiscal year 2024 to be $270-280 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.